ImmunityBio (NASDAQ:IBRX) Given Buy Rating at HC Wainwright

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Thursday, MarketBeat Ratings reports. They presently have a $15.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 63.40% from the stock’s current price. HC Wainwright also issued estimates for ImmunityBio’s FY2027 earnings at $0.10 EPS.

IBRX has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group upped their target price on ImmunityBio from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price on shares of ImmunityBio in a report on Wednesday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

ImmunityBio Stock Down 8.2%

Shares of IBRX stock traded down $0.82 during trading hours on Thursday, hitting $9.18. 21,482,898 shares of the company’s stock traded hands, compared to its average volume of 20,619,063. The stock’s 50 day simple moving average is $8.54 and its 200 day simple moving average is $7.96. The stock has a market cap of $9.73 billion, a PE ratio of -9.46 and a beta of 0.02. ImmunityBio has a 12 month low of $1.95 and a 12 month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million. As a group, equities research analysts expect that ImmunityBio will post -0.44 EPS for the current fiscal year.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the sale, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This trade represents a 44.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the sale, the director owned 2,777,788 shares of the company’s stock, valued at $29,861,221. This trade represents a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 66.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Markowski Investments purchased a new position in shares of ImmunityBio during the 2nd quarter valued at $29,000. GAMMA Investing LLC lifted its position in shares of ImmunityBio by 262.2% during the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after buying an additional 2,756 shares during the last quarter. Hollencrest Capital Management purchased a new position in shares of ImmunityBio during the 2nd quarter valued at $44,000. Western Wealth Management LLC purchased a new position in shares of ImmunityBio during the 1st quarter valued at $44,000. Finally, Geneos Wealth Management Inc. raised its stake in shares of ImmunityBio by 579.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock valued at $44,000 after purchasing an additional 4,907 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA expands ANKTIVA’s label: The FDA approved ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors, in addition to the previously covered carcinoma-in-situ population. The broader label significantly increases the drug’s addressable market and commercial potential. FDA Expands ANKTIVA Approval article
• Positive Sentiment: Durable Phase 2/3 results support ANKTIVA: Long-term QUILT-3.032 data showed a 71% complete response rate in 100 patients, median response duration of 26.6 months, and responses lasting beyond 53 months. Among responding patients, three-year cystectomy-free survival was 84%, suggesting many may avoid bladder-removal surgery. ImmunityBio Phase 3 data article
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reaffirmed its Buy rating and raised its FY2027 EPS estimate to $0.10 from $0.07, while maintaining a $15 price target. Jefferies also reportedly lifted its target to $14, indicating analysts see additional upside if ANKTIVA adoption accelerates.
• Neutral Sentiment: Options activity turned unusually active: Traders purchased 26,656 call options, approximately 44% above average volume. This may reflect increased bullish speculation, but it does not guarantee sustained buying in the shares.
• Negative Sentiment: Investors remain cautious despite the clinical breakthrough: IBRX declined as traders appeared to take profits following the FDA-related rally and evaluate whether the expanded approval and strong data can translate into rapid sales growth. The company remains loss-making, and its latest reported quarter missed the consensus EPS estimate.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.